Purchase Order 75N91020P00551

The National Cancer Institute awarded a purchase order to Qiagen, LLC for $356,555 on July 29, 2020, for clinical interpretation of genomic variants from large next-generation sequencing panels, whole exome sequencing, and whole transcriptome sequencing in support of cancer research and diagnostics. Work is performed in Germantown, Maryland. The order calls for software-supported clinical interpretation services to evaluate, classify, and interpret genomic variants from cancer patient sequencing data according to established guidelines, with Qiagen providing software licenses, staff training, and analysis of specified numbers of gene panels and exomes, with monthly and final reporting required. Ultimate completion was set for July 29, 2022. The procurement originated from a sole-source Special Notice posted May 22, 2020, with due date June 2, 2020; the agency determined only Qiagen qualified due to its customized implementation already in use and expertise developed through prior contracts. In fiscal year 2020, Qiagen invoiced $10 thousand against this order and self-performed all work without subcontractors.